# Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

> **NCT00277316** · PHASE2 · TERMINATED · sponsor: **Symphony Evolution, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** XL999

## Key facts

- **NCT ID:** NCT00277316
- **Lead sponsor:** Symphony Evolution, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-12
- **Primary completion:** 2007-02
- **Final completion:** 2007-06
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Development of XL999 was stopped due to cardiac toxicities in the subjects
- **Last updated:** 2010-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00277316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00277316, "Study of XL999 in Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00277316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*